A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2011
10/18/2011	US8039462 Methods and compositons for stimulating neurogenesis and inhibiting neuronal degeneration
10/18/2011	US8039461 Physical states of a pharmaceutical drug substance
10/18/2011	US8039460 CGRP receptor antagonists
10/18/2011	US8039459 Nicotinic receptor agonists for the treatment of inflammatory diseases
10/18/2011	US8039458 HIV integrase inhibitors
10/18/2011	US8039457 Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues
10/18/2011	US8039456 Method of stimulating the motility of the gastrointestinal system using ipamorelin
10/18/2011	US8039455 Macrocyclic compounds useful as BACE inhibitors
10/18/2011	US8039454 Macrolide compounds with antibiotic and antineoplastic properties
10/18/2011	US8039453 Vinca derivatives
10/18/2011	US8039452 Antifungal medicinal compositions
10/18/2011	US8039451 Boron-containing small molecules
10/18/2011	US8039450 Boron-containing small molecules as anti-inflammatory agents
10/18/2011	US8039448 N-acylated chitinous polymers and methods of use thereof
10/18/2011	US8039447 Derivatives of hyaluronic acid, their preparation process and their uses
10/18/2011	US8039444 Antisense permeation enhancers
10/18/2011	US8039443 polynucleotides that bind to proteins that regulate cell growth and division; used as antitumor agents alone or in combination with known cytotoxic agents
10/18/2011	US8039442 Compounds and methods for treatment of sickle cell disease or complications associated therewith
10/18/2011	US8039441 Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and process for their manufacture
10/18/2011	US8039222 Treatment and prevention of tissue damage
10/18/2011	US8039219 Method of using GPR35 to identify metabolic-stabilizing compounds
10/18/2011	US8039026 Methods for treating skin pigmentation
10/18/2011	US8039020 Composition exhibiting enhanced formulation stability and delivery of topical active ingredients
10/18/2011	US8039019 Pharmaceutical formulation containing a biguanide and an angiotensin antagonist
10/18/2011	US8039018 Solid dosage form of wetted heparin
10/18/2011	US8039012 Topical compositions for anti-aging and methods of using same
10/18/2011	US8039011 A temperature change composition including a neurosensory component, e.g., menthol, and a first phase change component having a first phase change temperature between 15-40 degrees C., e.g., hydrocarbon, wax; encapsulated evaporative cooling agent; refreshing; durability; receptivity with other skin item
10/18/2011	US8039009 Modified release formulations of memantine oral dosage forms
10/18/2011	US8039000 Nucleic acid and corresponding protein entitled 158P3D2 useful in treatment and detection of cancer
10/18/2011	US8038988 Method of enhancing hair growth
10/18/2011	US8038986 Immunogenic compositions and diagnostic and therapeutic uses thereof
10/18/2011	CA2673449C A combination comprising combretastatin and anticancer agents
10/18/2011	CA2654700C Transdermal patch
10/18/2011	CA2649549C Methods of treating cell proliferative disorders by using pyrimidinediamine compounds
10/18/2011	CA2633086C Fexofenadine suspension formulation
10/18/2011	CA2598294C Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivative
10/18/2011	CA2590939C Aminopyrimidine compounds and methods of use
10/18/2011	CA2589894C Radionuclide-chitosan complex having an improved stabilized gelatin in administering them to the body and their preparation method
10/18/2011	CA2579207C Morpholine compound
10/18/2011	CA2560058C A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
10/18/2011	CA2552107C Pyrrolotriazine compounds as kinase inhibitors
10/18/2011	CA2551167C Aminoalcohol derivatives
10/18/2011	CA2535533C Aqueous pharmaceutical solution comprising oxymetazoline and/or xylometazoline
10/18/2011	CA2530774C Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
10/18/2011	CA2515197C Pyrazolopyridine derivates
10/18/2011	CA2503730C Cytarabine monophosphate prodrugs
10/18/2011	CA2498210C Combination of a) n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and b) a histone deacetylase inhibitor for the treatment of leukemia
10/18/2011	CA2494557C Fused heterocyclic isoxazoline derivatives and their use as anti-depressants
10/18/2011	CA2494297C Aqueous 2,6-diisopropylphenol pharmaceutical compositions
10/18/2011	CA2494049C Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
10/18/2011	CA2494010C Modafinil polymorphic forms
10/18/2011	CA2487123C Patch containing fentanyl
10/18/2011	CA2484038C Estrogen receptor modulators
10/18/2011	CA2480438C Novel use of the extract of processed ginseng and saponin isolated therefrom
10/18/2011	CA2478813C Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors
10/18/2011	CA2475312C N-aminoacetyl-pyrrolidine-2-carbonitriles and their use as ddp-iv inhibitors
10/18/2011	CA2470199C Composition based on etyllinoleate and triethylcitrate for the treatment of seborrhea and acne
10/18/2011	CA2469459C Methods and compositions for the diagnosis of asthma
10/18/2011	CA2469152C Pharmaceutical composition for the treatment of parkinson's disease
10/18/2011	CA2466906C Pharmaceutical composition comprising a prostaglandin e1
10/18/2011	CA2466499C Use of a mixture of sodium hyaluronate and chondroitin sulfate for the treatment of osteoarthritis
10/18/2011	CA2462345C Dimeric compounds and their use as anti-viral agents
10/18/2011	CA2453441C Lyophilizing composition of drug-encapsulating polymer micelle and method for preparation thereof
10/18/2011	CA2443950C Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
10/18/2011	CA2440644C Inhibitors of integrin .alpha.v.beta.6
10/18/2011	CA2434927C Pharmaceutical compositions with antibiotic activity
10/18/2011	CA2419842C New aporphine esters and their use in therapy
10/18/2011	CA2403218C Embolic compositions
10/18/2011	CA2399801C A concentrated, non-foaming solution of quaternary ammonium compounds and methods of use
10/18/2011	CA2398018C Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
10/18/2011	CA2360275C Novel stabilized activated derivatives of carbamic acid, their process of preparation and their use for the preparation of ureas
10/18/2011	CA2337328C Biocompatible polymers, preparation method and compositions containing same
10/18/2011	CA2252986C Process for preparing functional recombinant tissue factor
10/18/2011	CA2232237C Reagents and methods useful for detecting diseases of the breast
10/18/2011	CA2228944C Liposomal phosphodiester, phosphorothioate, and p-ethoxy oligonucleotides
10/14/2011	CA2736998A1 A composition
10/13/2011	WO2011127465A2 Ship inhibitors and uses thereof
10/13/2011	WO2011127456A2 Method for formulating large diameter synthetic membrane vesicles
10/13/2011	WO2011127406A2 Acridines as inhibitors of haspin and dyrk kinases
10/13/2011	WO2011127388A2 Inverse agonists and neutral antagonists for the tsh receptor
10/13/2011	WO2011127350A1 Hepatitis c virus inhibitors
10/13/2011	WO2011127337A2 Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
10/13/2011	WO2011127300A1 Crystalline forms of prasugrel salts
10/13/2011	WO2011127256A1 Protein-poly(2-oxazoline) conjugates for enhanced cellular delivery and transport across biological barriers
10/13/2011	WO2011127244A2 ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED pH EFFECT
10/13/2011	WO2011127240A1 Methods of using diacerein as an adjunctive therapy for diabetes
10/13/2011	WO2011127235A1 Combination therapy for the treatment of dementia
10/13/2011	WO2011127232A2 Substituted androst-4-ene diones
10/13/2011	WO2011127222A1 Diagnosis and treatment of melanoma through nuak2 assessment and modulation
10/13/2011	WO2011127221A1 Gamma-polyglutamic acid-based ocular irrigating solutions
10/13/2011	WO2011127202A2 Methods for identifying and using inhibitors of casein kinase 1 epsilon isoform for inhibiting the growth and/or proliferation of myc-driven tumor cells
10/13/2011	WO2011127200A2 Methods of treatment using 3-bromopyruvate and other selective inhibitors of atp production
10/13/2011	WO2011127196A1 Ketorolac compositions for corneal wound healing
10/13/2011	WO2011127192A2 Antimetastatic compounds
10/13/2011	WO2011127180A1 Compositions and methods for inhibiting expression of cd274/pd-l1 gene
10/13/2011	WO2011127179A1 Glycomimetic compounds and methods to inhibit infection by hiv
10/13/2011	WO2011127176A2 Methods for treating or screening for compounds for the treatment of sepsis
10/13/2011	WO2011127170A2 Methods for diagnosing and treating asthma
10/13/2011	WO2011127143A1 Process for preparing benzoxaboroles
10/13/2011	WO2011127106A1 Pyrimidinylpiperidinyloxypyridinone analogues as gpr119 modulators

1 ... 1521 1522 1523 1524 1525 1526 1527 1528 1529 1530 1531 1532 1533 1534 1535 1536 1537 1538 1539 1540 1541 ... 7860